NO20060329L - Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse - Google Patents

Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse

Info

Publication number
NO20060329L
NO20060329L NO20060329A NO20060329A NO20060329L NO 20060329 L NO20060329 L NO 20060329L NO 20060329 A NO20060329 A NO 20060329A NO 20060329 A NO20060329 A NO 20060329A NO 20060329 L NO20060329 L NO 20060329L
Authority
NO
Norway
Prior art keywords
pth
administered
composition
pharmaceutical compositions
oral use
Prior art date
Application number
NO20060329A
Other languages
English (en)
Inventor
Lisbeth Bonlokke
Original Assignee
Nycomed Danmark Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark Aps filed Critical Nycomed Danmark Aps
Publication of NO20060329L publication Critical patent/NO20060329L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

Farmasøytisk sammensetning for oral administiering omfattende PTH, der in vitro fiigjøring av PTH - når den blir testet i en oppløsningstest av farmacopoeia standard - blir forsinket med minst 2 timer og med en gang fiigjøringen starter, blir minst 90% v/v slik som for eksempel, minst 99% av all PTH inneholdt i sammensetningen fiigjort i løpet av for det meste 2 timer. Sammensetningen kan også omfatte en kalsium inneholdende forbindelse og/eller et vitamin, D. Særlig blir PTH administiert i kombinasjon med en kalsium inneholdende forbindelse for behandling eller forhindring av ben-relaterte sykdommer, slik at I) en effektiv mengde PTH blir administiert for å senke plasmanivået av endogen PTH, og II) en effektiv mengde PTH bhr administiert for å oppnå en toppkonsentiasjon av PTH med en gang det endogene PTH-nivået er senket. Dette innebærer en potensiell terapeutisk eller profylaktisk kur for ben-relaterte forstyrrelser inkludert osteoporose.
NO20060329A 2003-07-04 2006-01-20 Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse NO20060329L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301035 2003-07-04
PCT/DK2004/000482 WO2005002549A1 (en) 2003-07-04 2004-07-05 Parathyroid hormone (pth) containing pharmaceutical compositions for oral use

Publications (1)

Publication Number Publication Date
NO20060329L true NO20060329L (no) 2006-01-20

Family

ID=33560711

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060329A NO20060329L (no) 2003-07-04 2006-01-20 Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse

Country Status (9)

Country Link
US (1) US20070155664A1 (no)
EP (1) EP1643978A1 (no)
JP (1) JP2007525472A (no)
KR (1) KR20060105735A (no)
CN (1) CN1816324A (no)
CA (1) CA2531136A1 (no)
IL (1) IL172769A0 (no)
NO (1) NO20060329L (no)
WO (1) WO2005002549A1 (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
SI1915137T1 (sl) 2005-08-10 2013-12-31 Add Advanced Drug Delivery Technologies, Ltd. Pripravek z nadzorovanim sproščanjem za peroralno dajanje
RU2507196C2 (ru) 2005-09-19 2014-02-20 Эмисфире Текнолоджис, Инк. Кристаллические формы динатриевой соли n-(5-хлорсалицилоил)-8-аминокаприловой кислоты
KR20140053419A (ko) * 2005-11-17 2014-05-07 노파르티스 아게 약제학적 조성물
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
ES2436028T3 (es) * 2006-06-23 2013-12-26 Radius Health, Inc. Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno
EP2762132A1 (en) 2007-04-25 2014-08-06 Cytochroma Inc. Controlled Release 25-Hydroxyvitamin D
DK2148684T3 (da) 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
WO2009137104A1 (en) * 2008-05-09 2009-11-12 Radius Health, Inc. Combination therapy for breastcancer comprising an antiestrogenic agent
AU2009283821B2 (en) * 2008-08-18 2014-05-29 Entera Bio Ltd. Methods and compositions for oral administration of proteins
US20100256060A1 (en) * 2009-04-02 2010-10-07 Unigene Laboratories Inc. Peptide pharmaceuticals for nasal delivery
US8682440B2 (en) 2009-08-03 2014-03-25 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
BR112012003511A2 (pt) * 2009-09-09 2019-09-24 Asahi Kasei Pharma Corp agente para o tratamento ou prevenção de osteoporose, preparação de combinação ou kit de tratamento, e, agente para a inibição ou prevenção de fraturas ósseas
WO2011048144A1 (en) * 2009-10-20 2011-04-28 Herbonis Ag Composition comprising solanum glaucophyllum for preventing and/or treating hypocalcaemia and for stabilizing blood calcium levels
FR2953139B1 (fr) * 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CN102552919B (zh) * 2010-12-15 2018-03-27 上海安博生物医药股份有限公司 一种给药组合物及其制备和使用方法
AU2010339907A1 (en) * 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US8562589B2 (en) 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
EP2568806B1 (en) 2010-05-12 2016-05-11 Radius Health, Inc. Therapeutic regimens
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) * 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN102144982B (zh) * 2011-03-30 2012-12-12 江苏神龙药业有限公司 一种米诺膦酸片及其制备方法
US20150374725A1 (en) * 2013-02-20 2015-12-31 Prelief Inc. Methods and compositions for treating and preventing intestinal injury and diseases related to tight junction dysfunction
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
PL3122426T3 (pl) 2014-03-28 2023-05-15 Duke University Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
JP6359390B2 (ja) * 2014-09-05 2018-07-18 テルモ株式会社 インプラントデバイスおよびインプラントデバイス植え込み具
CA2975578A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Treatment of hypoparathyroidism
TWI747893B (zh) 2016-03-28 2021-12-01 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 維生素ｄ治療之方法
EP3474841B1 (en) 2016-06-22 2022-03-16 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
MX2019001850A (es) * 2016-08-17 2019-05-15 Entera Bio Ltd Formulaciones para administracion oral de principios activos.
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형
CN117417263A (zh) 2017-01-05 2024-01-19 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
CN111372586B (zh) 2017-11-20 2023-07-25 诺麦塔制药有限公司 包含chp的骨丢失疾病的预防、改善或治疗用组合物
CN112423844A (zh) 2018-07-04 2021-02-26 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
US11857559B2 (en) * 2018-09-10 2024-01-02 Aurobindo Pharma Ltd. Pharmaceutical composition comprising Canagliflozin, process of preparation and use thereof
JP2022522550A (ja) * 2019-03-08 2022-04-20 アニヤ バイオファーム インク． 副甲状腺ホルモンアナログの経口製剤および治療
KR102115353B1 (ko) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
US20230151075A1 (en) * 2019-12-03 2023-05-18 The Johns Hopkins University Parathyroid hormone attenuates low back pain and osteoarthritic pain
WO2022133555A1 (pt) * 2020-12-23 2022-06-30 Lithocálcio Indústria, Comércio, Importação, Exportação E Representação Ltda. Composição farmacêutica sólida contendo vitamina d e sal de cálcio, método para tratar ou prevenir condições relacionadas a baixa ingestão e/ou maior necessidade de cálcio, uso da composição farmacêutica sólida e produto farmacêutico ou suplementar
KR20240013402A (ko) * 2022-07-22 2024-01-30 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 골다공증 예방 또는 치료를 위한 경구용 약학적 조성물 및 이의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
ATE195252T1 (de) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
CN1228708A (zh) * 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe

Also Published As

Publication number Publication date
US20070155664A1 (en) 2007-07-05
IL172769A0 (en) 2006-04-10
EP1643978A1 (en) 2006-04-12
CA2531136A1 (en) 2005-01-13
WO2005002549A1 (en) 2005-01-13
JP2007525472A (ja) 2007-09-06
KR20060105735A (ko) 2006-10-11
CN1816324A (zh) 2006-08-09

Similar Documents

Publication Publication Date Title
NO20060329L (no) Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse
Boursinos et al. Do steroids, conventional non-steroidal anti-inflammatory drugs and selective Cox-2 inhibitors adversely affect fracture healing
NO20052019L (no) Blanding for a inhibere sekresjon av magesyre
KR950002150B1 (ko) 레보도파 메틸에스테르를 함유하는 제약 조성물
Quiding et al. TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction
UA94916C2 (ru) Композиция тразодона для введения один раз в день
ES2383433T3 (es) Formulación farmacéutica de apomorfina para administración bucal
MXPA04012998A (es) Modulares de receptores nucleares de hormonas esteroideas triciclicos.
RU2009111391A (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
US6521266B1 (en) Composition for growth hormone production and release, appetite suppression, and methods related thereto
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
EA200870368A1 (ru) Антибиотические композиции с модифицированным высвобождением и способ их получения
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
CO4810383A1 (es) Sal tartrato de un dipeptido sustituido
DE60041147D1 (de) Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen
WO2012174158A2 (en) Administration of benzodiazepine
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
KR20050057673A (ko) Ｊｎｋ 억제제를 이용한 통증의 치료
CA2486859A1 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
RU2007133435A (ru) Способ комбинированного лечения и применимые для этого сочетания лекарственных средств
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
EP1543826B1 (en) Concentrated aqueous solution of ambroxol
ES2250726T3 (es) Utilizacion de extractos de ginkgo biloba para preparar un medicamento destinado a tratar la sarcopenia.
EA038052B1 (ru) Комбинация, содержащая пальмитоилэтаноламид, для лечения хронической боли
US10456365B2 (en) Methods and formulations for supporting and promoting bone health

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application